248 related articles for article (PubMed ID: 23448557)
41. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab.
Segal O; Ferencz JR; Cohen P; Nemet AY; Nesher R
Isr Med Assoc J; 2013 Jul; 15(7):352-5. PubMed ID: 23943979
[TBL] [Abstract][Full Text] [Related]
42. Diurnal intraocular pressure efficacy of the timolol-brimonidine fixed combination and the timolol-dorzolamide fixed combination as a first choice therapy in patients with pseudoexfoliation glaucoma.
Yüksel N; Gök M; Altıntaş O; Cağlar Y
Curr Eye Res; 2011 Sep; 36(9):804-8. PubMed ID: 21851166
[TBL] [Abstract][Full Text] [Related]
43. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
44. Effect of dorzolamide and timolol on ocular pressure: blood flow relationship in patients with primary open-angle glaucoma and ocular hypertension.
Fuchsjäger-Mayrl G; Georgopoulos M; Hommer A; Weigert G; Pemp B; Vass C; Garhöfer G; Schmetterer L
Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1289-96. PubMed ID: 19850848
[TBL] [Abstract][Full Text] [Related]
45. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy.
Liu JH; Medeiros FA; Slight JR; Weinreb RN
Ophthalmology; 2009 Mar; 116(3):449-54. PubMed ID: 19157559
[TBL] [Abstract][Full Text] [Related]
46. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
Tamer C; Oksüz H
Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
[TBL] [Abstract][Full Text] [Related]
47. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin).
Falkenstein IA; Cheng L; Freeman WR
Retina; 2007 Oct; 27(8):1044-7. PubMed ID: 18040242
[TBL] [Abstract][Full Text] [Related]
48. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.
Omay E; Elgin U; Sen E; Yilmazbas P
Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098
[TBL] [Abstract][Full Text] [Related]
49. The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial.
Baiza-Durán LM; Alvarez-Delgado J; Contreras-Rubio AY; Medrano-Palafox J; De Luca-Brown A; Casab-Rueda H; Cortés-Gastélum MA; Garcidueñas-Mejía MJ; Gómez-Bastar P; Gil-Carrasco F; Hartleben-Matkin C; Jiménez-Román J; Moreno-Marín ML; Paczka-Zapata JA; Velasco-Gallegos G; Vergara-Sinta M
Ann Ophthalmol (Skokie); 2009; 41(3-4):174-8. PubMed ID: 20214051
[TBL] [Abstract][Full Text] [Related]
50. Prophylactic selective laser trabeculoplasty in the prevention of intraocular pressure elevation after intravitreal triamcinolone acetonide injection.
Bozkurt E; Kara N; Yazici AT; Yuksel K; Demirok A; Yilmaz OF; Demir S
Am J Ophthalmol; 2011 Dec; 152(6):976-981.e2. PubMed ID: 21861972
[TBL] [Abstract][Full Text] [Related]
51. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy.
Yannuzzi NA; Patel SN; Bhavsar KV; Sugiguchi F; Freund KB
Am J Ophthalmol; 2014 Aug; 158(2):319-327.e2. PubMed ID: 24814167
[TBL] [Abstract][Full Text] [Related]
52. Preventive Dorzolamide-Timolol for Rising Intraocular Pressure During Steep Trendelenburg Position Surgery.
Molloy BL; Cong X; Watson C
AANA J; 2016 Jun; 84(3):189-96. PubMed ID: 27501654
[TBL] [Abstract][Full Text] [Related]
53. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide.
Clineschmidt CM; Williams RD; Snyder E; Adamsons IA
Ophthalmology; 1999 Dec; 106(12 Suppl):17-24. PubMed ID: 10598693
[TBL] [Abstract][Full Text] [Related]
54. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients.
Janulevicienë I; Harris A; Kagemann L; Siesky B; McCranor L
Acta Ophthalmol Scand; 2004 Dec; 82(6):730-7. PubMed ID: 15606472
[TBL] [Abstract][Full Text] [Related]
55. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.
Nuzzi R; Tridico F
Semin Ophthalmol; 2015 Mar; 30(2):129-35. PubMed ID: 24171832
[TBL] [Abstract][Full Text] [Related]
56. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
Ozturk F; Ermis SS; Inan UU
Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215
[TBL] [Abstract][Full Text] [Related]
57. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.
Good TJ; Kimura AE; Mandava N; Kahook MY
Br J Ophthalmol; 2011 Aug; 95(8):1111-4. PubMed ID: 20702430
[TBL] [Abstract][Full Text] [Related]
58. [Immediate changes in intraocular pressure after an intravitreal injection of 2.5 mg of bevacizumab].
Wu L; Evans T
Arch Soc Esp Oftalmol; 2010 Nov; 85(11):364-9. PubMed ID: 21277463
[TBL] [Abstract][Full Text] [Related]
59. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
[TBL] [Abstract][Full Text] [Related]
60. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components.
Strohmaier K; Snyder E; DuBiner H; Adamsons I
Ophthalmology; 1999 Dec; 106(12 Suppl):1-9. PubMed ID: 10598691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
